Prophylactic Cryoprecipitate Transfusion in patients undergoing Scoliosis Surgery: A randomized-controlled trial
Phase 1
Recruiting
- Conditions
- Anaesthesia
- Registration Number
- PACTR202112813900074
- Lead Sponsor
- Rabab Saber Mahrous
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
ASA grade I-III, adolescents who were to undergo
major elective scoliosis surgery expected to last at least 4 hours
Exclusion Criteria
bleeding disorder, pre-existing thrombocytopenia
and/or anemia, prior thromboembolic disease, hemorrhagic diathesis, established
hypersensitivity to fibrinogen concentrate, active infectious disease, overweight
(BMI>35), left ventricular ejection fraction below 45%, significant cardiac
arrhythmias, valvular lesions, perioperative renal insufficiency, impaired hepatic
function, allergy to any drug used in this study, preoperative infection and intake of
acetylsalicylate within 2 weeks or nonsteroidal anti-inflammatory drugs within 7
days before surgery
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint was the volume of peri-operative transfused blood products <br>(pRBCs, FFP and concentrated platelets) during the whole stay in hospital.
- Secondary Outcome Measures
Name Time Method A secondary endpoint was the volume of peri-operative blood loss, defined as the <br>sum of the blood loss measurements during surgery, and the precisely measured <br>volume of postoperative blood loss during the stay on the ICU.